TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1937996
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg) given i.v. 1, 2 and 3 h before surgery
Study: 21378581
Drug: Castile soap
Normalized name: CASTILE SOAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castile soap solution
Study: 9430592
Drug: Implications for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implications for treatment development
Study: 2818278
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol therapy (twice daily)
Study: 27812689
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of weekly trastuzumab (ACTH)
Study: 23222289
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg, 2 capsules)
Study: 21631929
Drug: Roflumilast (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (500 μg tablet once daily; Day 2-18) and concomitant formoterol (24 μg twice daily; Day 12-18)
Study: 21631929
Drug: Formoterol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (24 μg twice daily; Day 2-18) and concomitant roflumilast (500 μg once daily; Day 9-18)
Study: 21631929
Drug: Roflumilast and
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast and formoterol administered concomitantly
Study: 21631929
Drug: Roflumilast and
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast and formoterol administered individually
Study: 19459520
Drug: ARB (Telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (Telmisartan 80 mg/day)
Study: 19459520
Drug: Control (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ACE inhibitors only, Enalapril 40 mg/day)
Study: 8038358
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg t.d.s. plus tetracycline 500 mg q.d.s. for 14 days (OMP/TCN)
Study: 8038358
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg in the morning plus tetracycline 500 mg q.d.s. along with bismuth subsalicylate tablets 2 q.d.s. for 14 days (OMP/TCN/BSS)
Study: 3055941
Drug: Tri-buffered aspirin
Normalized name: Tri-Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tri-buffered aspirin
Study: 31134713
Drug: Concurrent Cogmed
Normalized name: SUCTION TUBE ATTACH DEVICE CONMED #34870
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Cogmed and metacognitive strategy training
Study: 28061873
Drug: Melatonin 4
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 4 mg enterally administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first.
Study: 28061873
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first.
Study: 17048435
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg DEC plus 400 mg ABZ
Study: 17048435
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg DEC alone
Study: 12663845
Drug: Stimulant users
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant users (cocaine or amphetamines)
Study: 10492061
Drug: Atovaquone-proguanil (1000/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone-proguanil (1000/400 mg) with artesunate (250 mg)
Study: 10492061
Drug: Atovaquone-proguanil (1000/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone-proguanil (1000/400 mg) without artesunate
Study: 8909421
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose oral methotrexate
Study: 2275513
Drug: Low-dosage oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage oral contraceptives
Study: 29160424
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard physical therapy without non-invasive ventilation)
Study: 22316073
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg for children ≥ 12 months, and 10 mg for those < 12 months) once daily for seven days
Study: 22316073
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for seven days
Study: 17984834
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + Daclizumab (steroid-free)
Study: 17984834
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + Mycophenolate Mofetil (MMF) + Daclizumab (steroid-free)
Study: 14627912
Drug: Steroid-free protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free protocol
Study: 10371880
Drug: NUPRO Gold
Normalized name: Nupro Chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUPRO Gold active gel
Study: 10371880
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel without the active agent
Study: 7631676
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation for 3 weeks
Study: 30835574
Drug: Hormonal oral
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal oral contraceptive use
Study: 28874181
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein and low glycemic index diet (1.3-1.4 g/kg/day)
Study: 25914962
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with interval debulking (NACT‐IDS)
Study: 21170734
Drug: 3,000 mg
Normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Study: 21170734
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Study: 21170734
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Study: 19008771
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (given to 69% of children)
Study: 19770794
Drug: Simvastatin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (lower than therapeutically equivalent dose)
Study: 19770794
Drug: Simvastatin (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (not prescribed a higher milligram dose)
Study: 19770794
Drug: Atorvastatin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (control group)
Study: 8148290
Drug: Epinephrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (5 micrograms/mL)
Study: 30020510
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab with pertuzumab
Study: 30020510
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab without pertuzumab
Study: 22016458
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (immobilization and physiotherapy)
Study: 18067679
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (SP)
Study: 11449082
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined oral HRT (2 mg of estradiol plus 1 mg of norethisterone acetate)
Study: 28025442
Drug: 1% Matricaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Matricaria chamomilla L. mouthwash
Study: 25668505
Drug: Topical β-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical β-glucan
Study: 13678479
Drug: Clarithromycin ER
Normalized name: Clarithromycin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin ER 500 mg once daily for 5 days
Study: 13678479
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 500 mg three times daily for 10 days
Study: 10490554
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment with alteplase
Study: 8739554
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg daily for 16 days)
Study: 8739554
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg, SC)
Study: 6765541
Drug: 15:85% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15:85% human insulin mixture
Study: 6765541
Drug: 10:90% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10:90% human insulin mixture
Study: 6765541
Drug: 20:80% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20:80% human insulin mixture
Study: 6765541
Drug: 15:85% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15:85% and 20:80% human insulin mixtures
Study: 27435303
Drug: Intravenous fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish oil (FO) supplementation after the first week of PN
Study: 24766295
Drug: Rikkunshito (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (2.5 g three times a day for 8 weeks)
Study: 22926604
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (50 to 300 mg/d, mean = 132.2 mg)
Study: 15050907
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg daily in 3-month blocks)
Study: 15050907
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg every 3 months as a single infusion)
Study: 15050907
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg daily) in previously untreated patients
Study: 15050907
Drug: Alendronate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (40 mg daily) in previously treated patients
Study: 7761376
Drug: Combination levorin
Normalized name: Levorin
DrugBank: Candicidin (DB01152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination levorin + furadonin + nitroxoline
Study: 28738708
Drug: HBB 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBB 40 mg
Study: 23116377
Drug: Children's Psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's Psychosocial Rehabilitation Treatment Adherence Measure (CTAM) for CPSR
Study: 23116377
Drug: Children's Psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's Psychosocial Rehabilitation Treatment Adherence Measure (CTAM) for psychotherapy
Study: 18705532
Drug: Fixed-dose amlodipine/benazepril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose amlodipine/benazepril (2.5/5 mg/day titrated to 5/10 mg/day)
Study: 18705532
Drug: Amlodipine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine monotherapy (5 mg/day titrated to 10 mg/day)
Study: 18705532
Drug: Fixed-dose amlodipine/benazepril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose amlodipine/benazepril
Study: 14564289
Drug: 7-mm tub
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-mm tub preparation design
Study: 14564289
Drug: 11-mm tub
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-mm tub preparation design
Study: 14564289
Drug: 7-mm box
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-mm box preparation design
Study: 14564289
Drug: 11-mm box
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-mm box preparation design
Study: 14564289
Drug: Box-shaped tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Box-shaped tooth preparation
Study: 10791875
Drug: Nucleoside analog
Normalized name: Nucleoside analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analog therapies
Study: 1363481
Drug: Verapamil (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (increased dose from 240 to 600 mg)
Study: 2879444
Drug: Nifedipine (50.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (50.0 ± 5.2 mg per day) + Atenolol (89.5 ± 25.7 mg per day)
Study: 2879444
Drug: Verapamil (460
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (460 ± 20 mg per day) + Enalapril (29.5 ± 5.0 mg per day)
Study: 2879444
Drug: Nifedipine (50.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (50.0 ± 5.2 mg per day)
Study: 2879444
Drug: Verapamil (460
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (460 ± 20 mg per day)
Study: 25089359
Drug: ACN-rich beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACN-rich beverage (juice with 983.7 mg/l ACN)
Study: 25089359
Drug: ACN-rich beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACN-rich beverage (smoothie with 840.9 mg/l ACN)
Study: 18717508
Drug: Oxymorphone immediate-release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone immediate-release (IR)
Study: 18717508
Drug: Oxymorphone extended-release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended-release (ER)
Study: 18717508
Drug: Titrated doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated doses of oxymorphone ER
Study: 16365493
Drug: Buffered prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered prilocaine (10 ml of prilocaine hydrochloride 2% buffered with 1 ml of sodium bicarbonate 8.4%)
Study: 16365493
Drug: Plain prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plain prilocaine (10 ml of plain prilocaine hydrochloride 2% solution)
Study: 14644397
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin 80 mg QD and avasimibe 750 mg QD
Study: 11021899
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. for 7 days (first phase)
Study: 11021899
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m. for 2 weeks (second phase)
Study: 8626843
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal system applied to the back for 24 hours
Study: 8626843
Drug: Testosterone transdermal
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone transdermal system applied to various sites (abdomen, back, chest, shin, thigh, upper arm) for 24 hours
Study: 1576117
Drug: D,L‐α‐tocopherol (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L‐α‐tocopherol (vitamin E) 1,000 IU/day for 7 days
Study: 6374766
Drug: Endocervical prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocervical prostaglandin E2 gel (0.5 mg in 2.5 ml)
Study: 6374766
Drug: Vaginal PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal PGE2 tablet (2.0 mg)
Study: 6374766
Drug: Endocervical prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocervical prostaglandin E2 gel (0.5 mg) in women with Bishop score 0-2
Study: 6374766
Drug: Vaginal PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal PGE2 tablet (2.0 mg) in women with Bishop score 0-2
Study: 31662396
Drug: Telemonitoring using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring using Sense4Baby CTG devices, Microlife BP monitor, daily telephone calls with an obstetric healthcare professional, and weekly hospital visits.
Study: 22834725
Drug: Psychodynamic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic or psychoanalytically oriented treatments (PAT), up to 80 sessions in the first year, potentially extended to 240-300 sessions over two to three years.
Study: 22834725
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), up to 60 sessions in the first year, potentially extended to 80 sessions focusing on maintenance and relapse prevention.
Study: 8858222
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose 12-15 mmol/l)
Study: 1634643
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (20 mg isosorbide-5-mononitrate)
Study: 1634643
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (20 mg isosorbide-5-mononitrate)
Study: 6519164
Drug: Piretanide (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (12 to 192 mg)
Study: 28003206
Drug: Dietary zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary zinc increase from 6 mg Zn/d to 10 mg Zn/d for 4 weeks
Study: 21401921
Drug: Topiramate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (up to 75 mg per day) with psychotherapy (n = 30)
Study: 18492379
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium suppository 100 mg (Voltarol) at the end of oocyte retrieval
Study: 17176187
Drug: Multidimensional family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional family therapy with family-focused techniques
Study: 17176187
Drug: Multidimensional family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional family therapy with adolescent-focused techniques
Study: 10883827
Drug: Antibiotic prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribed according to culture and sensitivity (Group A)
Study: 3535860
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lignocaine-prilocaine cream (EMLA)
Study: 24201696
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg perindopril daily for 20 weeks
Study: 20220293
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone undecanoate (im TU)
Study: 20220293
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (oral TU)
Study: 20220293
Drug: Transdermal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo gel (P)
Study: 11016387
Drug: Cryoablation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoablation therapy
Study: 11016387
Drug: Intercostal application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal application of local anesthetic agents (Control)
Study: 8879616
Drug: Purged PBPC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purged PBPC (75 micrograms/ml of ether lipid for 4 h at 37 degrees C)
Study: 23725995
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with implantable cardioverter defibrillator (ICD), n = 132
Study: 23725995
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with ICD, n = 132
Study: 21418447
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (cereal-lentil mixture providing 930 kcal and multivitamin micronutrient supplement)
Study: 19655825
Drug: OAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC plus atorvastatin 40 mg/day and ezetimibe 10 mg/day
Study: 18247250
Drug: Treatment Implementation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Implementation (TI) methods in a rehabilitation team‐training intervention
Study: 14760792
Drug: Tacrolimus 3
Normalized name: Tacrolimus 300 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 3 mg/day
Study: 14760792
Drug: Tacrolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 1.5 mg/day
Study: 9661016
Drug: DU-6859a 50
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 50 mg b.i.d. for 5 days
Study: 9661016
Drug: DU-6859a 100
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DU-6859a 100 mg b.i.d. for 5 days
Study: 9661016
Drug: Theophylline (TP)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (TP) 200 mg b.i.d. for 9 days
Study: 7595905
Drug: Losartan-HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-HCTZ combination therapy
Study: 7595905
Drug: Losartan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (both monotherapy and combination therapy)
Study: 31612482
Drug: Erenumab 28
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab 28 mg
Study: 21514032
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone once daily for 14 days after insemination
Study: 18444848
Drug: Daptomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (4 mg/kg) once daily for 5-14 days
Study: 18444848
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g) once daily for 5-14 days
Study: 18444848
Drug: Daptomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (4 mg/kg) once daily for 5-14 days with prior effective therapy
Study: 18444848
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g) once daily for 5-14 days with prior effective therapy